Yahoo Web Search

Search results

      • Novo Nordisk is an excellent long-term option Novo Nordisk's performance in 2023 wasn't a one-off or a fluke. The company's excellent financial results, proven innovative abilities, and leadership in the high-growth area of obesity care puts it in an excellent position to deliver outsized returns in the midterm.
      www.fool.com › investing › 2024/01/18
  1. People also ask

  2. Apr 15, 2024 · Novo Nordisk has been a good stock to buy over the years. The pharmaceutical company has produced a 21% total annualized return over the past 10 years, outperforming the S&P 500's average...

  3. 4 days ago · Valuation metrics show that Novo Nordisk A/S may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of NVO ...

  4. Feb 5, 2024 · Is Novo Nordisk a Hot Stock to Buy Now After its Spectacular Q4? Eric Volkman, The Motley Fool. Sun, Feb 4, 2024, 11:59 PM 4 min read. In this article: NOVO-B.CO. NVO. LLY. Two of the most...

  5. Mar 11, 2024 · Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.13 to $3.36 per share. NVO also boasts an average...

  6. Volume 3,195,358. Avg. Volume 4,355,373. Market Cap (intraday) 602.599B. Beta (5Y Monthly) 0.19. PE Ratio (TTM) 46.97. EPS (TTM) 2.88. Earnings Date Aug 7, 2024. Forward Dividend & Yield 1.37...

  1. People also search for